- Question from MasonG: Any new options for triple-negative breast cancer that have shown real promise?
- Answers - Eric Winer, M.D. The option that is the most encouraging is the PARP inhibitor Iniparib. In a preliminary study, it enhanced the effectiveness of chemotherapy and seemed to prolong survival. A more definitive study has been completed and we are waiting for the results.
On Wednesday, December 15, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 San Antonio Breast Cancer Symposium. Eric Winer, M.D. and Marisa Weiss, M.D. answered your questions about the latest updates on breast cancer risk, screening, and treatment in early and metastatic breast cancer.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.